DE69435261D1 - Menschlicher rezeptor h4-1bb - Google Patents

Menschlicher rezeptor h4-1bb

Info

Publication number
DE69435261D1
DE69435261D1 DE69435261T DE69435261T DE69435261D1 DE 69435261 D1 DE69435261 D1 DE 69435261D1 DE 69435261 T DE69435261 T DE 69435261T DE 69435261 T DE69435261 T DE 69435261T DE 69435261 D1 DE69435261 D1 DE 69435261D1
Authority
DE
Germany
Prior art keywords
receptor protein
human
protein
cells
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69435261T
Other languages
English (en)
Inventor
Byoung S Kwon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22404839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69435261(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Application granted granted Critical
Publication of DE69435261D1 publication Critical patent/DE69435261D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DE69435261T 1993-09-16 1994-09-15 Menschlicher rezeptor h4-1bb Expired - Lifetime DE69435261D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12279693A 1993-09-16 1993-09-16
PCT/US1994/010457 WO1995007984A1 (en) 1993-09-16 1994-09-15 Human receptor h4-1bb

Publications (1)

Publication Number Publication Date
DE69435261D1 true DE69435261D1 (de) 2010-02-25

Family

ID=22404839

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69435261T Expired - Lifetime DE69435261D1 (de) 1993-09-16 1994-09-15 Menschlicher rezeptor h4-1bb

Country Status (11)

Country Link
US (3) US8026353B2 (de)
EP (1) EP0719329B1 (de)
JP (2) JPH09503911A (de)
KR (2) KR100244960B1 (de)
AT (1) ATE454449T1 (de)
AU (1) AU697482B2 (de)
CA (2) CA2429027C (de)
DE (1) DE69435261D1 (de)
ES (1) ES2341631T3 (de)
NZ (1) NZ273838A (de)
WO (1) WO1995007984A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US7138500B1 (en) 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
ATE454449T1 (de) 1993-09-16 2010-01-15 Univ Indiana Res & Tech Corp Menschlicher rezeptor h4-1bb
US5928893A (en) * 1995-04-08 1999-07-27 Lg Chemical Ltd. Monoclonal antibody specific for human 4-1BB and cell line producing same
WO1997033898A1 (en) * 1996-03-15 1997-09-18 Human Genome Sciences, Inc. Human 4-1bb receptor splicing variant
US5874240A (en) * 1996-03-15 1999-02-23 Human Genome Sciences, Inc. Human 4-1BB receptor splicing variant
CN1232402A (zh) * 1996-10-11 1999-10-20 布里斯托尔-迈尔斯斯奎布公司 免疫调节的方法和组合物
AU747063B2 (en) * 1998-03-05 2002-05-09 Merckle Gmbh Utilization of CD137 in order to promote the proliferation of peripheral monocytes
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
ES2328025T3 (es) 2001-10-09 2009-11-06 Mayo Foundation For Medical Education And Research Mejoramiento de las respuestas inmunitarias por anticuerpos agonistas 4-1 bb.
JP2005536511A (ja) * 2002-07-15 2005-12-02 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ ４−１ｂｂ結合物質を用いる治療及び予防
US20060121030A1 (en) * 2002-12-16 2006-06-08 Herbert Schwarz Use of cd 137 antagonists for the treatment of tumors
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US20070253961A1 (en) * 2004-06-09 2007-11-01 Ulsan Industrial Education Foundation Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis
JP5303146B2 (ja) 2004-10-06 2013-10-02 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｂ７−ｈ１ならびに癌の診断、予後診断および処置の方法
US20060182744A1 (en) * 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
NZ568433A (en) * 2005-10-21 2012-07-27 Gtc Biotherapeutics Inc Milk-derived antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
US20110229460A1 (en) * 2008-05-01 2011-09-22 Gtc Biotherapeutics, Inc. anti-cd137 antibody as an agent in the treatment of inflammatory conditions
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
JPWO2011149025A1 (ja) * 2010-05-28 2013-07-25 株式会社上野忠 経口用体温上昇剤
MY169644A (en) * 2010-12-09 2019-04-24 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2824997C (en) 2011-01-18 2023-01-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
WO2015050663A1 (en) 2013-10-01 2015-04-09 Mayo Foundation For Medical Education And Research Methods for treating cancer in patients with elevated levels of bim
CN111514283A (zh) 2014-04-07 2020-08-11 诺华股份有限公司 使用抗cd19嵌合抗原受体治疗癌症
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
EP3171896A4 (de) 2014-07-23 2018-03-21 Mayo Foundation for Medical Education and Research Abzielung auf dna-pkcs und b7-h1 zur behandlung von krebs
EP4056588A1 (de) 2015-04-08 2022-09-14 Novartis AG Cd20-therapien, cd22-therapien und kombinationstherapien mit einer zelle zur expression des chimären antigen-rezeptors (car) cd19
WO2017075045A2 (en) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Antibodies to b7-h1
MX2019003886A (es) 2016-10-07 2019-08-05 Novartis Ag Receptores de antigenos quimericos para el tratamiento del cancer.
AU2018209452A1 (en) 2017-01-20 2019-07-18 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD137+ cells
AU2018301393A1 (en) 2017-07-11 2020-02-06 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
WO2019100052A2 (en) 2017-11-20 2019-05-23 Compass Therapeutics Llc Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2021170071A1 (en) 2020-02-28 2021-09-02 Shanghai Henlius Biotech, Inc. Anti-cd137 constructs, multispecific antibody and uses thereof
WO2021170067A1 (zh) 2020-02-28 2021-09-02 上海复宏汉霖生物技术股份有限公司 抗cd137构建体及其用途
CN114605541B (zh) * 2021-08-26 2023-08-29 北京大学深圳研究生院 一种抗4-1bb纳米抗体、编码基因及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560649A (en) 1981-10-15 1985-12-24 Cornell Research Foundation Assaying for hLH or hCG with immobilized hormone receptors
US4837306A (en) * 1985-02-25 1989-06-06 The Ontario Cancer Institute Method for selecting hybridomas producing antibodies specific to the P-glycoprotein cell suface antigen and a cDNA clone encoding the C-terminal portion of the antigen
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US7138500B1 (en) * 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
AU6827094A (en) 1993-05-07 1994-12-12 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
US7211259B1 (en) * 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
ATE454449T1 (de) 1993-09-16 2010-01-15 Univ Indiana Res & Tech Corp Menschlicher rezeptor h4-1bb
US5928893A (en) 1995-04-08 1999-07-27 Lg Chemical Ltd. Monoclonal antibody specific for human 4-1BB and cell line producing same

Also Published As

Publication number Publication date
CA2172165A1 (en) 1995-03-23
KR100271382B1 (en) 2000-11-15
AU7729494A (en) 1995-04-03
CA2429027A1 (en) 1995-03-23
WO1995007984A1 (en) 1995-03-23
NZ273838A (en) 1997-09-22
EP0719329B1 (de) 2010-01-06
AU697482B2 (en) 1998-10-08
CA2172165C (en) 2003-12-02
US20070117161A1 (en) 2007-05-24
US8026353B2 (en) 2011-09-27
US20020168719A1 (en) 2002-11-14
JP2006149389A (ja) 2006-06-15
ES2341631T3 (es) 2010-06-23
JPH09503911A (ja) 1997-04-22
KR100244960B1 (ko) 2000-02-15
ATE454449T1 (de) 2010-01-15
EP0719329A1 (de) 1996-07-03
CA2429027C (en) 2011-04-05
US20080312418A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
DE69435261D1 (de) Menschlicher rezeptor h4-1bb
Blazar et al. Recent advances in graft‐versus‐host disease (GVHD) prevention
Weiss et al. The role of the T3/antigen receptor complex in T-cell activation.
Lane et al. Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation.
Luescher et al. CD8 modulation of T-cell antigen receptor–ligand interactions on living cytotoxic T lymphocytes
US5747037A (en) Anti-GP39 antibodies
Fangmann et al. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides.
Mechtersheimer et al. Expression of the natural killer cell-associated antigens CD56 and CD57 in human neural and striated muscle cells and in their tumors
Bonnefoy et al. The low-affinity receptor for IgE (CD23) on B lymphocytes is spatially associated with HLA-DR antigens.
AU784634B2 (en) B7-H1, a novel immunoregulatory molecule
CA2246352A1 (en) Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
Wade et al. Structural compartmentalization of MHC class II signaling function
Bikah et al. A role for CD5 in cognate interactions between T cells and B cells, and identification of a novel ligand for CD5.
KR940007179A (ko) 시디40 (cd40)을 위한 수용성 리간드
US20100015153A1 (en) Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells and Antibodies That Identify the Same
JP2007126481A (ja) Ｔ細胞の不応答性を調節する方法
Lanier et al. Natural killer cells
US20030044416A1 (en) Nucleic acids encoding cd100 molecules
US7476385B2 (en) Methods of inhibiting IgE responses to thymus-dependent antigens with the anti-gp39 antibody MR1
Mortara et al. Therapy‐induced antitumor vaccination by targeting tumor necrosis factor‐α to tumor vessels in combination with melphalan
EP0742721B1 (de) Verfahren zur verlaengerter unterdrueckung der humoralen immunitaet
Rau et al. MHC-restricted and-unrestricted CD8 T cells: an evolutionary perspective
AU2667701A (en) Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same
Bromberg The biology of CD2: adhesion, transmembrane signal, and regulatory receptor of immunity
Macphail et al. L3T4+ cytotoxic T lymphocytes specific for class I H-2 antigens are activated in primary mixed lymphocyte reactions.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition